Journal of Medicinal Chemistry · 2023 · 17 citations · 21 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryLead OptimizationBreast Cancer PharmacotherapyHit-to-lead OptimizationHormonal Cancer TherapyLipophilicity OptimizationPotency OptimizationBioactive Conformation SelectionBreast Cancer Endocrine TherapyEstrogen PharmacologyEstrogen Receptor SignalingEstrogen ReceptorsHormone Receptor-positive Breast Cancer TherapyIn Vivo StudiesPhysicochemical Properties
Herein, we report the optimization of a meta-substituted series of selective estrogen receptor degrader (SERD) antagonists for the treatment of ER+ breast cancer. Structure-based design together with the use of modeling and NMR to favor the bioactive conformation led to a highly potent series of basic SERDs with promising physicochemical properties. Issues with hERG activity resulted in a strategy of zwitterion formation and ultimately in the identification of 38 . This compound was shown to be a highly potent SERD capable of effectively degrading ERα in both MCF-7 and CAMA-1 cell lines. The low lipophilicity and zwitterionic nature led to a SERD with a clean secondary pharmacology profile and no hERG activity. Favorable physicochemical properties resulted in good oral bioavailability in preclinical species and potent in vivo activity in a mouse xenograft model.
21
Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · Journal of Clinical Oncology · 2010 · 633 citations · Full text
Medicine, Oncology, Pharmacology +16
Chris De Savi, Robert H. Bradbury, Alfred A. Rabow et al. · Journal of Medicinal Chemistry · 2015 · 160 citations · Full text